Month: January 2022
2021 Cotton Project In Uzbekistan.2021 Cotton Project In Uzbekistan.NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
TORONTO, Jan. 31, 2022 (GLOBE NEWSWIRE) — Water Ways Technologies Inc. (TSXV: WWT) (FRA: WWT) (“WWT” or the “Company“), a global provider of Israeli-based agriculture technology, providing water irrigation solutions to agricultural producersis pleased to announce the signing, effective January 29, 2022, of two cotton drip irrigation projects in Uzbekistan with a total value of CAD$6,700,000.The projectsare repeat orders from a recurring customer who ordered a CAD$4,000,000 system in 2021, validating the quality of the Company’s products, service and customer relations.
The value of the first project in the Surkhandarya province of Uzbekistan...
Greenlight Re Innovations Receives In-Principle Approval to Establish Insurtech-focused Syndicate 3456
Written by Customer Service on . Posted in Public Companies.
GRAND CAYMAN, Cayman Islands, Jan. 31, 2022 (GLOBE NEWSWIRE) — Greenlight Re Innovations (“GRI”), part of Greenlight Capital Re, Ltd. (NASDAQ: GLRE) (“Greenlight Re” or the “Company”), has received ‘in-principle’ approval from Lloyd’s to establish an insurtech-focused syndicate. Syndicate 3456, which will commence operations in the second quarter of 2022, will be established under the innovative “Syndicate-in-a-box” (SIAB) model. It will be managed by Asta, the leading third-party managing agent at Lloyd’s.
Greenlight Re Innovations has built a market-leading reputation in early stage insurtech and has made 20 investments to date. Syndicate 3456 will enable Greenlight Re to provide capacity to its growing portfolio of insurtechs.
The Company will appoint Andy Gladwin as active underwriter for Syndicate 3456. Andy, who has over...
Point of care Diagnostics Market Size worth USD 36.21 billion by 2028 | Size, Share, Growth, Trends & Forecast
Written by Customer Service on . Posted in Mergers And Acquisitions.
Key Players Covered in the Point of Care Diagnostics Market Research Report Are F. Hoffmann-La Roche Ltd (Basel, Switzerland), Thermo Fisher Scientific Inc. (Massachusetts, U.S.), Abbott Laboratories (Illinois, U.S), Quest Diagnostics Incorporated (New Jersey, United States), BD (Franklin Lakes, U.S), bioMérieux SA (Marcy l’Etoile, France), Cardinal Health, Inc. (Ohio, U.S), Mesa Biotech (California, U.S), Cepheid (California, U.S), Trinity Biotech (Bray, Ireland), Quidel Corporation (San Diego, U.S.), Bio-Rad Laboratories Inc. (California, U.S) and other key market players
Pune, India, Jan. 31, 2022 (GLOBE NEWSWIRE) — The global Point of care Diagnostics Market size is projected to reach USD 36.21 billion by 2028, exhibiting a CAGR of -1.9% during the forecast period. The prevalence of several chronic disorders and the incorporation...
Membranes Market Expected Worth USD 10.73 Billion by 2028 | Membranes Industry Growth, Demand, Outlook and Forecast Report by Fortune Business Insights™
Written by Customer Service on . Posted in Mergers And Acquisitions.
Companies covered in membranes market are TORAY INDUSTRIES, INC. (Japan), DuPont (U.S.), SUEZ (France), KOCH (U.S.), Pentair plc (U.S.), TOYOBA (Japan), Hydranautics – A Nitto Group Company (U.S.), Pall Corporation (U.S.), Seccua GmbH (Germany), Synder Filtration (U.S.), and more players profiled
Pune, India, Jan. 31, 2022 (GLOBE NEWSWIRE) — The global membranes market is expected to reach USD 10.73 billion in 2028, exhibiting a CAGR of 6.3% during the forecast period. The growth is anticipated to be swelled by its increasing usage in the pharmaceutical and biomedical industries. They help in lowering the concentration of effluent stream and recovering significant substrate or intermediate. Fortune Business Insights™ gives this information in a published report titled, “Membranes Market, 2021-2028.” The report further mentions...
Ozop Energy Solutions Receives Department of Insurance Approval
Written by Customer Service on . Posted in Public Companies.
EV Insurance Company, Inc. DBA OZOP Plus Preparing for Launch
Florida, NY, Jan. 31, 2022 (GLOBE NEWSWIRE) — Ozop Energy Solutions. (OZSC), (“Ozop” or the “Company”), today announced its’ subsidiary, EV Insurance Company, Inc. has been granted a Conditional Certificate of Authority (the “CCA”) to operate as an insurance company by the Delaware Department of Insurance (the “DOI”) as of January 4, 2022. The Company also announced that on January 7, 2022, OZOP Plus was approved as the DBA for EV Insurance Company, Inc. The CCA will become final upon Ozop Plus meeting certain capital and surplus criteria of the DOI and continue to meet the accounting standards as set forth in the application for the Certificate of Authority. The Company has in hand the necessary capital and surplus required by the Delaware DOI.
As previously announced...
Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate
Written by Customer Service on . Posted in Public Companies.
Preclinical results demonstrate safe and efficient immune response with vaccine development showing promise of neutralizing activity for a range of variants
LAWRENCEVILLE, N.J., Jan. 31, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation DNA-based vaccines, announces it has engaged BIOQUAL, Inc., a preclinical testing contract research organization, to conduct a non-human primate (NHP) challenge study with Celsion’s DNA-based approach for a SARS-CoV-2 vaccine. The NHP pilot study follows the generation of encouraging mouse data and will evaluate the Company’s lead vaccine formulations for safety, immunogenicity and protection against SARS-CoV-2.
In completed preclinical studies, Celsion demonstrated safe and efficient immune responses...
Tornado Global Hydrovacs Poised to Grow in 2022
Written by Customer Service on . Posted in Public Companies.
Facility Enhancement, Management & Financial Strengthening, Product Line Extension
CALGARY, Alberta, Jan. 31, 2022 (GLOBE NEWSWIRE) — Tornado Global Hydrovacs Ltd. (“Tornado”, the “Company” or “we”) (TGH: TSX-V) is pleased to announce that it has strategically positioned itself for growth in 2022 and beyond. Over the past several months, Tornado has focused on implementing five strategic initiatives: (i) restructuring our management team by recruiting some of the top managers in the industry; (ii) relocating from a leased facility to a much larger and well equipped, owned facility in a better location; (iii) expanding our product line to match the needs of the excavation industry; (iv) taking a new approach to the way we distribute our products; and (v) strengthening our financial position to help fund the growth.
“These strategic...
Amedisys Announces Fourth Quarter and Year End Earnings Release and Conference Call Date
Written by Customer Service on . Posted in Public Companies.
BATON ROUGE, La., Jan. 31, 2022 (GLOBE NEWSWIRE) — Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and higher acuity care services, will report results for the fourth quarter and year ended December 31, 2021, after the market closes on February 23, 2022. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on February 24, 2022.
To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (877) 524-8416 (toll-free) or (412) 902-1028 (toll). A replay of the call will be available through March 24, 2022, by dialing (877) 660-6853 (toll-free) or (201) 612-7415 (toll) and entering access ID 13726704.
A live webcast of the call will be accessible through the Company website on the Investor Relations section at http://investors.amedisys.com.
About...
ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data
Written by Customer Service on . Posted in Public Companies.
ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial DataImmix Biopharma, Inc. (NASDAQ:IMMX)Manufactured IMX-110 to be utilized in both clinical trials:
2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”)
2022 planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab Clinical Trial in advanced solid tumorsAn image of IMX-110 is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/870f17c2-db33-4a8b-bccd-b09dc60f1e7d.
LOS ANGELES, Jan. 31, 2022 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced that it has initiated IMX-110 Good Manufacturing...
CUMULUS MEDIA Announces Conference Call to Discuss Fourth Quarter and Full Year 2021 Operating Results
Written by Customer Service on . Posted in Public Companies.
ATLANTA, Jan. 31, 2022 (GLOBE NEWSWIRE) — Cumulus Media Inc. (NASDAQ: CMLS) will host a conference call on Wednesday, February 23rd at 4:30 PM ET to discuss its fourth quarter and full year 2021 operating results. A press release containing a summary of these results will be issued before the call at approximately 4:00 PM ET.
To participate in the conference call, please register in advance using this link. NetRoadshow (NRS) is the service provider for this call. Registration requires a one-time only email address verification. Upon completing registration, a calendar invitation will follow with call access details, including a unique PIN, and replay details.
The conference call will also be broadcast live in listen-only mode through a link on the Company’s investor relations website at www.cumulusmedia.com/investors. This link...